Siemens Respiratory Test Kit Clinitest® Antigen Detection At-Home OTC COVID-19 Test Nasal Swab Sample 5 Tests per Kit - KT/5 - 11556711-KT

CLINITEST COVID-19 RAPID ANTI GEN OTC Item Id 1203770 MF Id# 11556711 Brand Clinitest® Manufacturer...


Siemens

11556711-KT

50 In Stock Sold Out 50



  • American Express
  • Diners Club
  • Discover
  • Mastercard
  • Shop Pay
  • Visa

Our Policies
Privacy policy
Payment policy
Shipping policy
Regular price $134.99 -Liquid error (snippets/product-price line 34): Computation results in '-Infinity'%
Regular price $134.99
 More payment options
Notify Me

Certain items may require either a prescription, medical license, or a business facility license to process. If your product falls in that category, we will reach out to you to obtain proper documentation.

If you already have a prescription, you may email us at support@healthcareorigin.com along with the order number.

CLINITEST COVID-19 RAPID ANTI GEN OTC

Item Id 1203770
MF Id# 11556711
Brand Clinitest®
Manufacturer Siemens
Country of Origin China
Application Respiratory Test Kit
CLIA Classified CLIA Waived
Contents 1 (5) Test Devices, (5) Sterile Swabs, (5) Extraction Tubes with Buffer and Tips, Instructions for Use
HCPCS U0002 (Disclaimer)
Number of Tests 5 Tests per Kit
Product Dating McKesson Acceptable Dating: we will ship >= 30 days
Purchase Program Type Standard Purchase
Reading Type Visual Read
Sample Type Nasal Swab Sample
Specialty Immunoassay
Test Format Cassette Format
Test Method Lateral Flow Chromatographic Immunoassay
Test Name At-Home OTC COVID-19 Test
Test Type Antigen Detection
Time to Results 15 Minute Results
UNSPSC Code 41116205

Features

  • The CLINITEST At-Home OTC COVID-19 Test is only for use under an FDA EUA: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-antigen-diagnostic-tests-sars-cov-2
  • Ships with minimum 30 Days Dating
  • The CLINITEST® At-Home OTC COVID-19 Test is a lateral flow chromatographic immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2
  • This test is authorized for non-prescription home use with self-collected anterior nasal (nares) swab samples from individuals aged 14 years or older with symptoms of COVID-19 within the first 7 days of symptom onset
  • This test is also authorized for non-prescription home use with adult-collected anterior nasal (nares) swab samples from individuals aged 2 years or older with symptoms of COVID-19 within the first 7 days of symptom onset
  • This test is also authorized for non-prescription home use with self-collected anterior nasal (nares) swab samples from individuals aged 14 years or older, or adult-collected anterior nasal (nares) swab samples from individuals aged 2 years or older, with or without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over three days with at least 24 hours (and no more than 48 hours) between tests
  • Results are for the identification of SARS-CoV-2 nucleocapsid protein antigen; antigen is generally detectable in anterior nasal (nares) swabs during the acute phase of infection
  • Positive results indicate the presence of viral antigens, but clinical correlation with past medical history and other diagnostic information is necessary to determine infection status
  • Positive results do not rule out bacterial infection or co-infection with other viruses
  • Individuals who test positive with CLINITEST® Rapid COVID-19 Antigen Self-Test should self-isolate and seek follow-up care with their physician or healthcare provider as additional testing may be necessary
  • Negative results should be treated as presumptive and confirmation with a molecular assay, if necessary, for patient management, may be performed
  • Negative results do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions
  • Individuals should provide all results obtained with this product to their healthcare provider for public health reporting
  • 86.5% Sensitivity; 99.3% Specificity
  • Qualitative; visually interpreted, no instrument required